Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients

• Published in: Journal of the neurological sciences Vol. 307; no. 1-2; pp. 41 - 45
• Main Authors: Christophi, George P., Christophi, Jennifer A., Gruber, Ross C., Mihai, Cornelia, Mejico, Luis J., Massa, Paul T., Jubelt, Burk
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 15.08.2011; Elsevier
• Subjects: Adjuvants, Immunologic - administration & dosage; Adult; Autoimmunity interferon; Biological and medical sciences; CNS demyelination; Cytokines; Dosage; Dose-Response Relationship, Drug; Down-Regulation - drug effects; Down-Regulation - immunology; Drug Monitoring - methods; EAE/TMEV; Efficacy; Female; Gene Expression Regulation - drug effects; Gene Expression Regulation - immunology; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - physiology; Inflammatory gene expression; Interferon beta-1a; Interferon-beta - administration & dosage; Interferon-beta - therapeutic use; Male; Medical sciences; Middle Aged; Multiple sclerosis; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - genetics; Multiple Sclerosis, Relapsing-Remitting - immunology; Neurology; Nuclear factor kappa-B (NF-κB); Peripheral immune cells; Secondary Prevention; Signal transducers and activators of transcription STAT; Signaling; Up-Regulation - drug effects; Up-Regulation - immunology; Inflammatory gene expression; Signaling; Multiple sclerosis; EAE/TMEV; Peripheral immune cells; Cytokines; Signal transducers and activators of transcription STAT; Efficacy; CNS demyelination; Nuclear factor kappa-B (NF-κB); Dosage; Autoimmunity interferon; Autoimmunity; Central nervous system; Signal transducers and activators of; Inflammatory disease; Transducer; Signal transduction; transcription STAT; Demyelination; Human; Nervous system diseases; Cytokine; Gene expression; Treatment; Central nervous system disease; Interferon

Interferon-β (IFN-β) is a current effective treatment for multiple sclerosis (MS) and exerts its therapeutic effects by down-modulating the systemic immune response and cytokine signaling. In clinical practice there are several formulations of interferon including a low dose of IFN-β 1a formulation...